Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548691 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 513
- Enrollment target
NCT00548691: Completed Phase 3 study, sponsored by American Regent.
NCT00548691 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 513 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00548691, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 513 participants
- Enrollment target
Study Summary
The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
Interventions
- DRUG Ferric Carboxymaltose
- DRUG Standard Medical Care (SMC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
What the finished NCT00548691 record still lists
NCT00548691 is an interventional study that assigns participants to a tested intervention. The registered 513 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 2 interventions - of which Ferric Carboxymaltose is the first listed.
NCT00548691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00548691 about?
NCT00548691 is a clinical study titled "Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients". The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
What is the current status of trial NCT00548691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 513 participants. The study started on 2007-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00548691?
The interventions under investigation include: Ferric Carboxymaltose (DRUG), Standard Medical Care (SMC) (DRUG).
Who is sponsoring clinical trial NCT00548691?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00548691's enrollment target sits among peer trials
513 727th of 2000 higher than 1,273 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- NCT06585488 · 514 participants · Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- NCT06716606 · 514 participants · Phase 3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia